Dec 15, 2023
January 26, 2025
This week’s newsletter included:
- Governor Cox Announces the Launch of the Utah Innovation Fund
- BioUtah Podcast Series: “Life Sciences in Action” with Meredith Krannich and Deno Himonas of Wilson Sonsini
- Halia Therapeutics Co-Founder David J. Bearss Featured in Utah Business
- Halia Therapeutics Dosed Its First Patient in Phase 2a Clinical Trial of HT-6184, a First-in-Class NLRP3-Inhibitor, for the Treatment of Lower-Risk Myelodysplastic Syndromes
- Central Texas Angel Network Makes Significant Investment in Phoenix PharmaLabs
- Inherent Biosciences Receives Investment from Utah Innovation Fund
- BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
- Two University of Utah Innovators Selected as National Academy of Inventors Fellows
- BioHive Wraps Up Food Drive
- Metrodora Hosts Governor Cox
- Technology Licensing Office at the University of Utah Announces New Processes for Tech Transfer
- 100 Companies Championing Women
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS